Pharmacoepidemiology and Drug Safety
Overview
Pharmacoepidemiology and Drug Safety is a reputable scientific journal that focuses on the study of the utilization, effectiveness, and safety of medications in real-world populations. It publishes high-quality research articles, reviews, and commentaries, providing valuable insights into the field of pharmacoepidemiology and promoting evidence-based decision-making in drug safety and public health.
Details
Details
Abbr.
Pharmacoepidemiol Drug Saf
Publisher
Wiley
Start
1992
End
Continuing
Frequency
Twelve no. a year, 2004-
p-ISSN
1053-8569
e-ISSN
1099-1557
Country
United Kingdom
Language
English
Specialties
Public Health
Pharmacology
Pharmacology
Metrics
Metrics
h-index / Ranks: 2665
109
SJR / Ranks: 3193
1106
CiteScore / Ranks: 5824
4.50
JIF / Ranks: 4138
2.6
Recent Articles
1.
Nafie M, Parker V, McClellan M, Hendricks-Sturrup R
Pharmacoepidemiol Drug Saf
. 2025 Mar;
34(3):e70127.
PMID: 40084391
Background: International harmonization of real-world data and evidence (RWD/E) standards is a goal among real-world data/real-world evidence (RWD/E) policy stakeholders. The Duke-Robert J. Margolis Institute for Health Policy developed an...
2.
Hennessy S, Atsuta Y, Hill S, Rago L, Juhaeri J
Pharmacoepidemiol Drug Saf
. 2025 Mar;
34(3):e70117.
PMID: 40070104
Data from sources other than traditional randomized clinical trials are known as real-world data (RWD), and the evidence derived from the review and analysis of RWD is known as real-world...
3.
Okonkwo J, Williams E, Sadjadi R, Schneeweiss S, Anderson-Smits C, Ay H, et al.
Pharmacoepidemiol Drug Saf
. 2025 Mar;
34(3):e70123.
PMID: 40025632
Purpose: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune condition of the peripheral nervous system. The validity of the CIDP diagnosis code in claims data is unclear. Methods: We...
4.
Pottegard A
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(3):e70119.
PMID: 40012278
No abstract available.
5.
Daungsupawong H, Wiwanitkit V
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(3):e70122.
PMID: 40010379
No abstract available.
6.
Cho E, Son M, Kim Y, Kim A, Seo S, Kim S
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(3):e70116.
PMID: 39985369
No abstract available.
7.
Kahrs J, Nickel K, Wood M, Dublin S, Durkin M, Osmundson S, et al.
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(3):e70115.
PMID: 39979792
Purpose: Studies using insurance claims data to identify pregnancies are rarely able to directly assess the validity of the pregnancy/delivery. Inpatient versus outpatient delivery claims may provide different levels of...
8.
Heyward J, Segal J, Mehta H, Murray J
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(2):e70100.
PMID: 39961795
Background: The use of real-world data is increasing to examine immune-related adverse event (irAE) incidence and risk factors in immune checkpoint inhibitor (ICI) users. We aimed to validate five case...
9.
Vasilakis-Scaramozza C, Persson R, Kafatos G, Neasham D, Hagberg K, Jick S
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(2):e5860.
PMID: 39961733
Purpose: Assess the validity of the Clinical Practice Research Datalink (CPRD) Aurum Mother-Baby Link (MBL). Methods: We assessed the validity of CPRD Aurum MBL pairs using several strategies. Our study...
10.
Hoffman S, Kalloo G, Lanes S, Jamal-Allial A, Sponholtz T, Brooks C, et al.
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(2):e70109.
PMID: 39953813
Purpose: Many post-authorization safety studies focus on congenital malformations and rely on diagnosis codes found in US data sources. However, no authoritative standards exist for identifying and classifying malformations in...